Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

intranasal foralumab

- PMLiVE

Tiziana to develop intranasal foralumab for type 1 diabetes

Approximately 4.7 million people in the UK are currently living with diabetes

- PMLiVE

Merck KGaA’s MS drug put on partial clinical hold by FDA

Laboratory results suggested there were two cases of drug-induced liver injury during the phase 3 studies

- PMLiVE

UK launches ‘revolutionary’ trial for progressive MS patients

Octopus is assessing whether existing drugs can be used to help slow disease progression

- PMLiVE

Sanofi reports positive new data for multiple sclerosis treatment tolebrutinib

It is estimated that there are over 130,000 people living with the condition in the UK alone

- PMLiVE

Tiziana’s foralumab shows continued clinical improvement in secondary progressive MS

MS affects around 700,000 people in Europe and approximately 2.5 million people worldwide

- PMLiVE

New UK study finds most MS patients not offered fatigue treatments

Of 4,367 patients surveyed, 30.8% reported having been offered at least one treatment for fatigue

- PMLiVE

World-first trial launches in UK to assess stem cell transplants as first-line MS treatment

The £2.3m StarMS study will compare AHSCT with four other drug treatments

- PMLiVE

Immunic reports promising new data for MS treatment

The treatment helped to lower the rate of confirmed disability worsening over time

- PMLiVE

Roche enters into second collaboration with Jnana to address complex drug targets

The Boston-based biotech will receive an upfront payment of $50m

- PMLiVE

Tiziana completes enrolment of first patient cohort in MS expanded access programme

Foralumab has already demonstrated positive results in patients with non-active SPMS

- PMLiVE

Tiziana starts enrolment in secondary progressive MS expanded access programme

MS affects around 700,000 people in Europe and approximately 2.5 million people worldwide

- PMLiVE

BMS confirms COVID-19 vaccine immune response in Zeposia-treated MS patients

Over 92% of patients in the analyses mounted a serological response following vaccination

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links